Robert E Conway, a director of Nivalis Therapeutics, Inc., just received 7,650 options from the company. The strike price of the options received was $11.31, and these expire on January 01, 2028. Conway now owns at least 7,650 options on the company.
Some additional info was provided as follows:
The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant.
100% of the shares subject to the option become vested and exercisable on January 2, 2019.
The above information was disclosed in a filing to the SEC. To see the filing, click here.
To recei ve a free e-mail notification whenever Nivalis Therapeutics, Inc. makes a similar move, sign up!
Other recent filings from the company include the following:
Nivalis Therapeutics, Inc. Just Filed Its Quarterly Report: Net Loss Per ShareWe... - Aug. 9, 2018
Nivalis Therapeutics, Inc.'s See Remarks just declared ownership of no shares of Nivalis Therapeutics, Inc. - Aug. 8, 2018
Nivalis Therapeutics, Inc.'s See Remarks was just granted 150,000 options - Aug. 8, 2018
Nivalis Therapeutics: Alpine Immune Sciences Strengthens Leadership Team With Appointment Of Mark Litton As President And Chief Operating Officer - Aug. 6, 2018